Profile
Michel Demeule is currently a Director at Katana Biopharma, Inc. He previously worked as a Research Director at Angiochem, Inc. and as a Researcher at the University of Quebec.
Dr. Demeule earned a doctorate degree from the University of Montréal in 1992.
Former positions of Michel Demeule
| Companies | Position | End |
|---|---|---|
| University of Quebec | Corporate Officer/Principal | - |
Katana Biopharma, Inc.
 Katana Biopharma, Inc. Hospital/Nursing ManagementHealth Services Katana Biopharma, Inc. operates oncology related technology platform. It develops a proprietary technology platform using peptides as a vehicle to specifically deliver existing cytotoxic agents to sortilin receptors, which are overexpressed on cancer cells. The company was founded by Richard Béliveau and Borhane Annabi in 2016 is headquartered in Montréal, Canada. | Director/Board Member | - |
Angiochem, Inc.
 Angiochem, Inc. Pharmaceuticals: MajorHealth Technology Angiochem, Inc. is a clinical-stage biotechnology company, which engages in the development of pharmaceutical drugs for brain diseases and brain-related disorders. It offers small molecules and biologics, for the treatment of central nervous system diseases including primary brain cancer, brain metastases, lysosomal storage diseases, and pain. The company founded by Richard Béliveau in 2003 and is headquartered in Montreal, Canada. | Chief Tech/Sci/R&D Officer | - |
Training of Michel Demeule
| University of Montréal | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 2 |
|---|---|
Angiochem, Inc.
Angiochem, Inc. Pharmaceuticals: MajorHealth Technology Angiochem, Inc. is a clinical-stage biotechnology company, which engages in the development of pharmaceutical drugs for brain diseases and brain-related disorders. It offers small molecules and biologics, for the treatment of central nervous system diseases including primary brain cancer, brain metastases, lysosomal storage diseases, and pain. The company founded by Richard Béliveau in 2003 and is headquartered in Montreal, Canada. | Health Technology |
Katana Biopharma, Inc.
Katana Biopharma, Inc. Hospital/Nursing ManagementHealth Services Katana Biopharma, Inc. operates oncology related technology platform. It develops a proprietary technology platform using peptides as a vehicle to specifically deliver existing cytotoxic agents to sortilin receptors, which are overexpressed on cancer cells. The company was founded by Richard Béliveau and Borhane Annabi in 2016 is headquartered in Montréal, Canada. | Health Services |
- Stock Market
- Insiders
- Michel Demeule